FI954007A0 - Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena - Google Patents

Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena

Info

Publication number
FI954007A0
FI954007A0 FI954007A FI954007A FI954007A0 FI 954007 A0 FI954007 A0 FI 954007A0 FI 954007 A FI954007 A FI 954007A FI 954007 A FI954007 A FI 954007A FI 954007 A0 FI954007 A0 FI 954007A0
Authority
FI
Finland
Prior art keywords
drug
phenyl
amino
substituted
acid derivatives
Prior art date
Application number
FI954007A
Other languages
English (en)
Swedish (sv)
Other versions
FI954007A (fi
Inventor
Klaus Urbahns
Siegfried Goldmann
Hans-Georg Heine
Bodo Junge
Rudolf Schohe-Loop
Henning Sommermeyer
Thomas Glaser
Reilinde Wittka
Vry Jean-Marie-Viktor De
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI954007A0 publication Critical patent/FI954007A0/fi
Publication of FI954007A publication Critical patent/FI954007A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/803Processes of preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
FI954007A 1994-08-29 1995-08-25 Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena FI954007A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4430638A DE4430638A1 (de) 1994-08-29 1994-08-29 Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel

Publications (2)

Publication Number Publication Date
FI954007A0 true FI954007A0 (fi) 1995-08-25
FI954007A FI954007A (fi) 1996-03-01

Family

ID=6526833

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954007A FI954007A (fi) 1994-08-29 1995-08-25 Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena

Country Status (20)

Country Link
US (1) US5670525A (fi)
EP (1) EP0705820A1 (fi)
JP (1) JPH0867670A (fi)
KR (1) KR960007565A (fi)
CN (1) CN1127114A (fi)
AU (1) AU697552B2 (fi)
CA (1) CA2156961A1 (fi)
CZ (1) CZ219895A3 (fi)
DE (1) DE4430638A1 (fi)
EE (1) EE9500059A (fi)
FI (1) FI954007A (fi)
HU (1) HUT74618A (fi)
IL (1) IL115072A (fi)
NO (1) NO308287B1 (fi)
NZ (1) NZ272851A (fi)
PL (1) PL310145A1 (fi)
RU (1) RU2154635C2 (fi)
SK (1) SK106595A3 (fi)
TW (1) TW419464B (fi)
ZA (1) ZA957187B (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024830A1 (en) * 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de) * 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US20050075359A1 (en) * 2003-03-14 2005-04-07 Rikako Kono Large conductance calcium-activated K channel opener
AU2006216566A1 (en) * 2005-02-24 2006-08-31 Janssen Pharmaceutica N.V. Novel pyridine derivatives as potassium ion channel openers
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (de) * 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
US9056832B2 (en) * 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof

Also Published As

Publication number Publication date
IL115072A (en) 1999-12-31
AU3020595A (en) 1996-03-14
EE9500059A (et) 1996-04-15
HU9502520D0 (en) 1995-10-30
SK106595A3 (en) 1997-01-08
NO953367D0 (no) 1995-08-28
NO308287B1 (no) 2000-08-28
KR960007565A (ko) 1996-03-22
HUT74618A (en) 1997-01-28
TW419464B (en) 2001-01-21
CA2156961A1 (en) 1996-03-01
JPH0867670A (ja) 1996-03-12
FI954007A (fi) 1996-03-01
RU2154635C2 (ru) 2000-08-20
US5670525A (en) 1997-09-23
AU697552B2 (en) 1998-10-08
NZ272851A (en) 1997-07-27
PL310145A1 (en) 1996-03-04
IL115072A0 (en) 1995-12-08
DE4430638A1 (de) 1996-03-07
CZ219895A3 (en) 1996-03-13
ZA957187B (en) 1996-04-17
NO953367L (no) 1996-03-01
EP0705820A1 (de) 1996-04-10
CN1127114A (zh) 1996-07-24

Similar Documents

Publication Publication Date Title
FI954007A0 (fi) Substituoitujen 4-fenyyli-6-amino-nikotiinihappojohdannaisten käyttö lääkeaineena
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
BR9510256A (pt) Derivados de ácido 3-aril-tetrônico
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
DK0851855T3 (da) Derivater af melatonin deraf som lægemiddel
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
DE19681287T1 (de) Orale Formulierung von 2-Methylthienobenzodiazepin
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
NO995245L (no) Anvendelse av tetrahydropyridinderivater for fremstilling av medisiner for å behandle sykdommer som bevirker demyelinisering
NO951147D0 (no) Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel
NO993627D0 (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
EE9700186A (et) Klavulaanhappe soolad
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
NO975680L (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
NO941073D0 (no) Fenylglycinamid av heterocykliske, substituerte fenyleddiksyrederivater
NO20003393L (no) FremgangsmÕte for fremstilling av en farmasøytisk formulering
NO307704B1 (no) 8-trifluormetylkinolinkarboksylsyre-derivat, medisinsk preparat inneholdende derivatet, samt anvendelse av et medisinsk preparat
NO953322L (no) Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler
DK0876367T3 (da) Trans apovincaminsyreesterderivater som lægemidler
DE69527684D1 (de) Herstellung von 3-oxy-5-oxo-6-Heptensäurederivaten
DE69502982D1 (de) Herstellung geschützter Aminothiazolylessigsäurederivate
NO940131D0 (no) Salter av 4-pyrimidinon-derivater for framasoeytisk anvendelse
NO960777D0 (no) Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter